Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Fluid biomarkers in Alzheimer disease.

Blennow K, Zetterberg H, Fagan AM.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221. Review.

2.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16. Review.

PMID:
20157306
3.

Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.

Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H.

Neuromolecular Med. 2012 Mar;14(1):65-73. doi: 10.1007/s12017-012-8171-4. Epub 2012 Feb 18.

PMID:
22350541
4.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2014;42(1):157-67. doi: 10.3233/JAD-140240.

PMID:
24820015
5.

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.

Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778.

PMID:
25790831
6.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
7.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
8.

Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.

Perneczky R, Alexopoulos P; Alzheimer's Disease euroimaging Initiative.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S425-S429.e1. doi: 10.1016/j.jalz.2013.09.006. Epub 2013 Nov 13.

9.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
10.

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM.

Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.

11.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

12.

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.

Babić M, Svob Štrac D, Mück-Šeler D, Pivac N, Stanić G, Hof PR, Simić G.

Croat Med J. 2014 Aug 28;55(4):347-65. Review.

13.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
14.

Cerebrospinal fluid biomarkers for Alzheimer's disease.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2009;18(2):413-7. doi: 10.3233/JAD-2009-1177. Review.

PMID:
19661632
15.

Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.

Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.

J Alzheimers Dis. 2014;42(3):777-88. doi: 10.3233/JAD-132216.

PMID:
24916543
16.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21. Review.

17.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385
18.

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.

Alcolea D, Martínez-Lage P, Sánchez-Juan P, Olazarán J, Antúnez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigué M, Guisasola MC, Sánchez Ruiz D, Marín Muñoz J, Calero M, Blesa R, Clarimón J, Carmona-Iragui M, Morenas-Rodríguez E, Rodríguez-Rodríguez E, Vázquez Higuera JL, Fortea J, Lleó A.

Neurology. 2015 Aug 18;85(7):626-33. doi: 10.1212/WNL.0000000000001859. Epub 2015 Jul 15.

PMID:
26180139
19.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

20.

Identifying and validating biomarkers for Alzheimer's disease.

Humpel C.

Trends Biotechnol. 2011 Jan;29(1):26-32. doi: 10.1016/j.tibtech.2010.09.007. Epub 2010 Oct 23. Review.

Supplemental Content

Support Center